Life expectancy of myasthenia gravis

Patients with myasthenia gravis generally have a life expectancy comparable to that of the general population when they receive active and effective treatment. The detailed analysis is as follows:

Myasthenia gravis is an autoimmune neurological disorder characterized by impaired neuromuscular transmission, leading to generalized muscle weakness. The exact cause of this disease remains unclear, but it is believed to be associated with abnormal immune function, genetic factors, and other elements. With timely and standardized treatment, most patients can achieve long-term survival. Therefore, once diagnosed with myasthenia gravis, prompt treatment is essential to alleviate symptoms and control disease progression. Treatment options include pharmacological therapy and surgical intervention. Medications such as methylprednisolone sodium succinate for injection and dexamethasone injection should be used strictly according to medical advice. For patients suspected of having thymoma or those who respond poorly to other treatments, thymectomy may be considered. After surgery, patients should avoid strenuous physical activity and schedule regular follow-up visits at the hospital. A diet rich in high-protein and high-vitamin foods—such as lean meat and eggs—is recommended to support recovery.